|
|
|
|
|
Teisinis statusas
Patentas neįsigaliojo (pagal EPK)
| (51) | INT.CL. | C07D 409/06 | |
| C07D 207/26 | |||
| C07D 207/273 | |||
| A61K 31/4015 | |||
| A61K 31/4025 | |||
| A61P 27/02 | |||
| A61P 27/06 | |||
| A61P 25/02 | |||
| A61P 17/14 | |||
| A61P 19/10 |
| (11) | Patento numeris | 3176162 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 16192438.6 |
| Europos patento paraiškos padavimo data | 2013-07-19 | |
| (97) | Europos patento paraiškos paskelbimo data | 2017-06-07 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2020-05-27 |
| (46) | Apibrėžties vertimo paskelbimo data |
| (30) | Numeris | Data | Šalis |
| 201261673514 P | 2012-07-19 | US | |
| 201361793929 P | 2013-03-15 | US |
| (72) |
BARRETT, Stephen Douglas, US
CISKE, Fred Lawrence, US
COLOMBO, Joseph Michael, US
ENDRES, Gregory William, US
GERMAIN, Bradlee David, US
KORNILOV, Andriy, US
KRAMER, James Bernard, US
UZIEBLO, Adam, US
MAXEY, Kirk M., US
|
| (73) |
Cayman Chemical Company, Inc.,
1180 E. Ellsworth Road, Ann Arbor, Michigan 48108,
US
|
| (54) | DIFLUOROLACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASE AND CONDITIONS |
| DIFLUOROLACTAM COMPOUNDS AS EP4 RECEPTOR-SELECTIVE AGONISTS FOR USE IN THE TREATMENT OF EP4-MEDIATED DISEASE AND CONDITIONS |